Piketty C, Bardin C, Gilquin J, Gairard A, Kazatchkine M D, Chast F
Department of Immunologie Clinique-INSERM U 430, Hôpital Broussais, Paris, France.
Clin Microbiol Infect. 2000 Mar;6(3):117-20. doi: 10.1046/j.1469-0691.2000.00014.x.
To investigate whether low ganciclovir serum levels in patients on maintenance oral ganciclovir therapy are associated with recurrence of CMV retinitis.
A prospective study of the plasma concentration of ganciclovir after initiation of maintenance oral ganciclovir therapy in 14 AIDS patients who had recovered from acute cytomegalovirus (CMV) retinitis.
Five of the 14 patients exhibited a mean time to recurrence of 37 days. The mean trough plasma concentration of ganciclovir in these patients after 1 month of oral ganciclovir therapy, was 0.40 +/- 0.30 mg/L. Nine patients had a mean time of progression of 263 days. The mean trough plasma concentration of ganciclovir in the latter patients was 0.80 +/- 0.60 mg/L.
Patients exhibiting trough plasma levels of ganciclovir below 0.6 mg/L may be at higher risk of progression than patients who exhibited levels above 0.6 mg/L.
研究接受口服更昔洛韦维持治疗的患者血清中更昔洛韦水平低是否与巨细胞病毒视网膜炎复发有关。
对14例从急性巨细胞病毒（CMV）视网膜炎中康复的艾滋病患者开始口服更昔洛韦维持治疗后其血浆中更昔洛韦浓度进行前瞻性研究。
14例患者中有5例复发的平均时间为37天。这些患者口服更昔洛韦治疗1个月后更昔洛韦的平均谷浓度为0.40±0.30mg/L。9例患者病情进展的平均时间为263天。后一组患者中更昔洛韦的平均谷浓度为0.80±0.60mg/L。
与更昔洛韦谷浓度高于0.6mg/L的患者相比，谷浓度低于0.6mg/L的患者病情进展风险可能更高。
Zotero 插件